JP2002502871A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002502871A5 JP2002502871A5 JP2000531161A JP2000531161A JP2002502871A5 JP 2002502871 A5 JP2002502871 A5 JP 2002502871A5 JP 2000531161 A JP2000531161 A JP 2000531161A JP 2000531161 A JP2000531161 A JP 2000531161A JP 2002502871 A5 JP2002502871 A5 JP 2002502871A5
- Authority
- JP
- Japan
- Prior art keywords
- use according
- subject
- disease
- amino
- propanesulfonic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 description 12
- 230000001225 therapeutic Effects 0.000 description 12
- SNKZJIOFVMKAOJ-UHFFFAOYSA-N Homotaurine Chemical compound NCCCS(O)(=O)=O SNKZJIOFVMKAOJ-UHFFFAOYSA-N 0.000 description 11
- 201000010099 disease Diseases 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- 206010001897 Alzheimer's disease Diseases 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 239000003814 drug Substances 0.000 description 6
- 230000016273 neuron death Effects 0.000 description 6
- 210000004556 Brain Anatomy 0.000 description 4
- 206010029350 Neurotoxicity Diseases 0.000 description 4
- 206010044221 Toxic encephalopathy Diseases 0.000 description 4
- 230000001537 neural Effects 0.000 description 4
- 230000002887 neurotoxic Effects 0.000 description 4
- 231100000228 neurotoxicity Toxicity 0.000 description 4
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 3
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 3
- 210000002540 Macrophages Anatomy 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 210000002569 neurons Anatomy 0.000 description 3
- FHELRCNMJVEIBX-UHFFFAOYSA-N 3-aminopropane-1-sulfonic acid;sodium Chemical compound [Na].NCCCS(O)(=O)=O FHELRCNMJVEIBX-UHFFFAOYSA-N 0.000 description 2
- 210000003169 Central Nervous System Anatomy 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 230000030833 cell death Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 210000003867 nerve cell Anatomy 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- KMGJRCNLDZGSFX-UHFFFAOYSA-M sodium;3-aminopropane-1-sulfonate Chemical compound [Na+].NCCCS([O-])(=O)=O KMGJRCNLDZGSFX-UHFFFAOYSA-M 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N sulfonic acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7429598P | 1998-02-11 | 1998-02-11 | |
| US60/074,295 | 1998-02-11 | ||
| US24839699A | 1999-02-10 | 1999-02-10 | |
| US09/248,396 | 1999-02-10 | ||
| PCT/IB1999/000354 WO1999040909A1 (fr) | 1998-02-11 | 1999-02-11 | Methode de modulation de l'activation des macrophages |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002502871A JP2002502871A (ja) | 2002-01-29 |
| JP2002502871A5 true JP2002502871A5 (fr) | 2008-11-20 |
| JP4574845B2 JP4574845B2 (ja) | 2010-11-04 |
Family
ID=26755484
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000531161A Expired - Lifetime JP4574845B2 (ja) | 1998-02-11 | 1999-02-11 | マクロファージの活性化を調節する方法 |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP1054664B1 (fr) |
| JP (1) | JP4574845B2 (fr) |
| AU (1) | AU2437899A (fr) |
| CA (2) | CA2632106A1 (fr) |
| CY (1) | CY1113205T1 (fr) |
| DK (1) | DK1054664T3 (fr) |
| ES (1) | ES2392391T3 (fr) |
| HK (1) | HK1032915A1 (fr) |
| IL (1) | IL137751A0 (fr) |
| MX (2) | MX2008014823A (fr) |
| NZ (2) | NZ568553A (fr) |
| PT (1) | PT1054664E (fr) |
| WO (1) | WO1999040909A1 (fr) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5605938A (en) | 1991-05-31 | 1997-02-25 | Gliatech, Inc. | Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate |
| WO1999059571A1 (fr) * | 1998-05-15 | 1999-11-25 | Neurochem, Inc. | Utilisation d'inhibiteurs d'amyloides pour une modulation de mort de cellules neuronales |
| US6310073B1 (en) | 1998-07-28 | 2001-10-30 | Queen's University At Kingston | Methods and compositions to treat glycosaminoglycan-associated molecular interactions |
| ES2331905T3 (es) * | 1999-04-28 | 2010-01-20 | Bellus Health (International) Limited | Composiciones y procedimientos para tratar la amiloidosis usando derivados sulfanato. |
| WO2001003680A2 (fr) * | 1999-07-09 | 2001-01-18 | Isis Innovation Limited | Composes destines a l'inhibition de maladies et a la preparation de cellules a transplanter |
| CA2395314A1 (fr) * | 1999-12-23 | 2001-11-15 | Neurochem, Inc. | Composes et methodes permettant la modulation de l'angiopathie cerebrale amyloide |
| US7105336B2 (en) * | 2002-10-07 | 2006-09-12 | Biogaia Ab | Selection and use of lactic acid bacteria for reducing inflammation caused by Helicobacter |
| BR0317747A (pt) * | 2002-12-24 | 2005-11-22 | Neurochem Int Ltd | Método de tratamento terapêutico concomitante de um indivìduo, composição farmacêutica, kit, uso de um primeiro agente e um segundo agente, e, métodos de prevenir ou tratar uma doença relacionada com amilóide-b, doença de alzheimer e insuficiência cognitiva suave |
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| US7253306B2 (en) | 2003-06-23 | 2007-08-07 | Neurochem (International) Limited | Pharmaceutical drug candidates and methods for preparation thereof |
| US20050142191A1 (en) | 2003-06-23 | 2005-06-30 | Neurochem (International) Limited | Pharmaceutical formulations of amyloid inhibiting compounds |
| JP2007516940A (ja) * | 2003-06-23 | 2007-06-28 | ニューロケム （インターナショナル） リミテッド | 改善された薬剤候補およびその調製法 |
| EP1836161B1 (fr) | 2004-12-22 | 2016-07-20 | BHI Limited Partnership | Methodes et compositions de traitement de maladies liees a l'amyloide |
| TW200716088A (en) * | 2005-04-15 | 2007-05-01 | Neurochem Int Ltd | Formulations and methods for treating amyloidosis |
| SG2014013437A (en) | 2005-11-30 | 2014-07-30 | Abbott Lab | Monoclonal antibodies and uses thereof |
| RU2442793C2 (ru) | 2005-11-30 | 2012-02-20 | Эбботт Лэборетриз | АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ |
| WO2007125385A2 (fr) | 2005-12-22 | 2007-11-08 | Neurochem (International) Limited | Traitement de troubles rénaux, de la néphropathie diabétique et des dyslipidémies |
| DK3851447T3 (da) | 2006-10-12 | 2023-12-04 | Bellus Health Inc | Fremgangsmåder, forbindelser, sammensætninger og vehikler til administration af 3-amino-1-propansulfonsyre |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| US20100311767A1 (en) | 2007-02-27 | 2010-12-09 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
| US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
| US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
| WO2009048539A2 (fr) | 2007-10-05 | 2009-04-16 | Genentech, Inc. | Anticorps monoclonal |
| WO2010094734A2 (fr) * | 2009-02-19 | 2010-08-26 | Biofocus Dpi B.V. | Procédés d'identification de composés utiles pour le diagnostic et le traitement de maladies liées à une inflammation |
| US8883855B2 (en) * | 2009-09-17 | 2014-11-11 | North Texas Medical Associates | Role of N-2-hydroxy-ethyl-piperazine-N′-2-ethane sulfonic acid (HEPES) in pain control and reversal of demyelinization injury |
| MX360403B (es) | 2010-04-15 | 2018-10-31 | Abbvie Inc | Proteinas de union a amiloide beta. |
| KR101713365B1 (ko) | 2010-07-30 | 2017-03-08 | 에이씨 이뮨 에스.에이. | 안전하고 기능적인 인간화 항 베타-아밀로이드 항체 |
| JP6147665B2 (ja) | 2010-08-14 | 2017-06-14 | アッヴィ・インコーポレイテッド | アミロイドベータ結合タンパク質 |
| WO2016163886A2 (fr) * | 2015-04-10 | 2016-10-13 | Clues2Cure International B.V. | Administration de taurine ou d'un analogue de celle-ci pour le traitement de lésions de cellules nerveuses |
| CN109381452A (zh) * | 2017-08-11 | 2019-02-26 | 江西青峰药业有限公司 | 乙基硫酸类化合物的应用及其制备方法 |
| CN109381453A (zh) * | 2017-08-14 | 2019-02-26 | 江西青峰药业有限公司 | 乙基硫酸钾在制备用于预防或治疗炎症性疾病药物中的应用 |
| CN109394746A (zh) * | 2017-08-15 | 2019-03-01 | 江西青峰药业有限公司 | 乙基硫酸铵在制备用于预防或治疗炎症性疾病药物中的应用 |
| WO2023212289A1 (fr) | 2022-04-28 | 2023-11-02 | Alzheon, Inc. | Tramiprosate pour le traitement de maladies liées à apoe4 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1144937A (fr) * | 1977-12-22 | 1983-04-19 | Dke J.E. Helgstrand | Derives aromatiques, composes pharmaceutiques et methode pour combattre les infections a virus |
| US5087618A (en) * | 1982-05-18 | 1992-02-11 | University Of Florida | Redox carriers for brain-specific drug delivery |
| US5463092A (en) * | 1989-11-22 | 1995-10-31 | Vestar, Inc. | Lipid derivatives of phosphonacids for liposomal incorporation and method of use |
| US5276059A (en) * | 1992-07-10 | 1994-01-04 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibition of diseases associated with amyloid formation |
| US5840294A (en) * | 1993-03-29 | 1998-11-24 | Queen's University At Kingston | Method for treating amyloidosis |
| EP1060750B1 (fr) * | 1993-03-29 | 2005-12-07 | Queen's University At Kingston | Acide propane-1,3-disulfonique et ses sels pharmaceutiquement acceptables pour le traitement de l'amyloidose |
| US5643562A (en) * | 1993-03-29 | 1997-07-01 | Queen's University Of Kingston | Method for treating amyloidosis |
| WO1999008685A1 (fr) * | 1997-08-18 | 1999-02-25 | Queen's University At Kingston | Composes de phosphono-carboxylate conçus pour le traitement de l'amylose |
| US5869469A (en) * | 1997-08-18 | 1999-02-09 | Queen's University At Kingston | Phosphonocarboxylate compounds for treating amyloidosis |
-
1999
- 1999-02-11 NZ NZ568553A patent/NZ568553A/en unknown
- 1999-02-11 DK DK99903869.8T patent/DK1054664T3/da active
- 1999-02-11 WO PCT/IB1999/000354 patent/WO1999040909A1/fr active Application Filing
- 1999-02-11 NZ NZ550199A patent/NZ550199A/en not_active IP Right Cessation
- 1999-02-11 MX MX2008014823A patent/MX2008014823A/es active IP Right Grant
- 1999-02-11 PT PT99903869T patent/PT1054664E/pt unknown
- 1999-02-11 AU AU24378/99A patent/AU2437899A/en not_active Abandoned
- 1999-02-11 MX MXPA00007815A patent/MXPA00007815A/es active IP Right Grant
- 1999-02-11 JP JP2000531161A patent/JP4574845B2/ja not_active Expired - Lifetime
- 1999-02-11 CA CA002632106A patent/CA2632106A1/fr not_active Abandoned
- 1999-02-11 ES ES99903869T patent/ES2392391T3/es not_active Expired - Lifetime
- 1999-02-11 IL IL13775199A patent/IL137751A0/xx not_active IP Right Cessation
- 1999-02-11 CA CA002320224A patent/CA2320224C/fr not_active Expired - Lifetime
- 1999-02-11 EP EP99903869A patent/EP1054664B1/fr not_active Expired - Lifetime
-
2001
- 2001-05-24 HK HK01103601.4A patent/HK1032915A1/xx not_active IP Right Cessation
-
2012
- 2012-10-16 CY CY20121100954T patent/CY1113205T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002502871A5 (fr) | ||
| CA2301378A1 (fr) | Composition pharmaceutique stabilisee d'un anti-inflammatoire non steroidien et d'une prostaglandine | |
| IL139229A0 (en) | Drug delivery system comprising a tightly compacted solid medicament stock | |
| CA2307018A1 (fr) | Systeme osmotique de liberation de medicament | |
| CA2492081A1 (fr) | Compositions pharmaceutiques comprenant du dextromethorphan et de la quinidine pour traiter des troubles neurologiques | |
| CA2326517A1 (fr) | Nouvelles formes galeniques de meloxicame a administrer par voie orale | |
| CA2446435A1 (fr) | Derives 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine | |
| CA2375908A1 (fr) | Inhibiteurs de recaptage de noradrenaline hautement selectifs et leurs methodes d'utilisation | |
| ATE515265T1 (de) | Vitamin d und dessen analoge zur behandlung vom tumoren und anderen hyperproliferativen erkrankungen | |
| WO2001039762A3 (fr) | Methodes de traitement de tumeurs | |
| WO1997048391A3 (fr) | Methodes et compositions a base de r-ibuprofene | |
| FR2798065B1 (fr) | Utilisation de la nicotine ou de ses derives dans un medicament pour le traitement des maladies neurologiques, notamment la maladie de parkinson | |
| CA2387486A1 (fr) | Utilisation de dipyridamole ou de mopidamol dans la fabrication d'un medicament de traitement et de prevention de troubles de la microcirculation lies a la fibrine | |
| AU7425391A (en) | Use of n-alkylated 1, 4-dihydropyridinedicarboxylic acid esters as medicaments, new compounds and processes for their preparation | |
| CA2143610A1 (fr) | Utilisation de norastemizole pour le traitement de troubles allergiques | |
| JP2003520193A (ja) | Ｒ（−）−ケトプロフェンを用いる神経障害性疼痛、耳鳴り、およびその他の障害治療のための方法および組成物 | |
| WO2022026622A3 (fr) | Traitement de maladies virales | |
| WO2001012214A3 (fr) | Mofetilmycophenolate associe a peg-ifn-alpha | |
| AU2021204517A1 (en) | Combination of opioids and n-acylethanolamines | |
| MXPA02009603A (es) | Terapias de dosis divididas con actividad de deterioro vascular. | |
| BR0009327A (pt) | Composição farmacêutica para a terapia de sintomas do trato urinário inferior | |
| CA2469702A1 (fr) | Utilisation de la darifenacine dans le traitement de mictions imperieuses induites par une vessie hyperactive | |
| WO1997044045A1 (fr) | Melatonine combinee a des analgesiques | |
| CA2515259A1 (fr) | Agent therapeutique pour maladie associee aux hemorroides | |
| GB2189703A (en) | Vinpocetine |